Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That’s because IHUB is for pump and dumps.
Nice close on Friday. News is coming... just a matter of time.
Every time good news comes out.... we drop.
I’m hoping some bad news comes to get this going again.
Man.... at this rate... we will be a penny stock soon!
News coming.... soon.
Yes.... I agree.
Get out of here with your nonsense! If you think Biden got 80 million votes.... you are just plain stupid!
Me either.... but I suspect they are there to grant political influence.
Busy.... new book s as almost finished.
Started our own tv show on CTN twice a week... 6 PM Friday and 10 PM Tuesday... CST. Also on YouTube.
Prophecy in the Spotlight
Stocks:
NK stock has saved my account!
PTLR is another with great potential.
Financials Tuesday.
I’m up 4X in crypto
How you doing Plano
.005 now.... what’s going on here?
Just curious if you are still here.
No where to go but up. This was equivalent of around $75 at pre split price
Yes.... finally.
Wonder how clays shorters are doing?
3:05a ET 12/21/2020 - BusinessWire
ImmunityBio and NantKwest to Merge, Creating a Leading Immunotherapy and Cell Therapy Company
Mentioned: NK
ImmunityBio, a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced they have entered into an agreement to merge in a stock-for-stock transaction. The combination will create a leading immunotherapy and cell therapy company focused on oncology and infectious disease.
Up $3.00-$4.00 premarket
Up big premarket!
Good.... I love to see shorts lose money.
Nice move today. This is coming back.
I bought 300 more after hours at $11:40
Looking for this to come right back.
Haha.
Are you still in Texas?
Yes... and have written several books since 2014. I am on TV every Friday night at 7:00 pm EST
On CTN.
I’m up in PFE
but my big winner is NK
Doing well. Travel a lot. Hosting two TV shows.
Hey Plano.. long time!
Always has to be pull backs. Relax....
Yup.... I still have 40% of my shares. Made a fortune!
$9.80
And.. what has this to do with NK?
Is someone buying the shell?
Almost hit $10.00
Unbelievable
Wowzers!!!!!!!
Yehaaa... great day!
Very impressive results..... from the December 16th news
Data Highlights Include:
Of 9 patients treated, efficacy results include a disease control rate of 78% (7/9 patients) and an overall response rate of 67% (6/9 patients).
2 out of 9 patients to date have ongoing complete responses with durations ranging from 8 to 11 months, with a 3rd patient demonstrating a partial response (near complete response) in the target lesion after initiation of targeted and endocrine therapy off-study.
To date, 7 patients are alive with durations of response ranging from 2 to 12 months with 4 patients remaining on study. Median progression-free survival rate is 13.7 months.
All patients were treated in an outpatient setting with treatment generally safe and well tolerated and no observed cytokine release syndrome.
No immune related SAEs were attributed to the immunotherapy investigational agents
All patients had at least 1 grade ≥ 3 TRAE, primarily chemotherapy-related neutropenia or anemia. Grade ≥ 3 haNK-related AEs, namely fever and fatigue, were observed in 2 patients.
Early data from peripheral blood analysis demonstrate clonal selection occurs with the immunotherapy regimen enabling targeted therapy tailored to patient specific mutations identified via next generation sequencing.
"The approximately 10-20% of breast cancer patients who are triple negative are faced with a grim prognosis with limited treatment options. These results are clinically significant, with overall response rates and complete response rates in this highly refractory, advanced metastatic patient population," said Dr. Chaitali Nangia, a Hematologist/Oncologist with the Chan Soon-Shiong Immuno-Oncology Network and study co-author. "Importantly, these responses to treatment are also durable, with median progression free survival exceeding 13 months compared to historical controls of approximately 3 months in this heavily pretreated population. We also observed a positive safety and tolerability profile, with no cytokine release syndrome. Taken together, these efficacy and safety results point to the emergence of a new treatment paradigm for TNBC."
Another great day here